Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib as Pre-Modulation in DLBCL Patients Receiving CAR-T-Cell Therapy
NCT05757219Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- May 2023
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of itacitinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Moffitt Cancer Center. Started May 2023; status: recruiting.
02
Drugs
itacitinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05757219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05757219.